Incyte Corp. said Monday that the Food and Drug Administration approved Opzelura as a topical repigmentation treatment for patients with nonsegmental vitiligo. Vitiligo is an autoimmune disease that can cause patients to lose color in patches on their hair and skin. Opzelura’s wholesale acquisition cost is $1,950 for a 60-gram tube, according to a spokesperson for the company. The therapy last year received FDA approval as a treatment for mild to moderate atopic dermatitis, generating $12.7 million in revenue in the first quarter of the year. At that time, CEO Hervé Hoppenot said the therapy “is an important growth driver” for Incyte. The company’s stock is up 7.4% this year, while the S&P 500 has declined 18.9%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
0
0